Ultragenyx Pharmaceutical (RARE) Capital Expenditures (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Capital Expenditures for 14 consecutive years, with $1.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Capital Expenditures changed 0.0% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $6.0 million (down 59.24% YoY), while the FY2025 annual figure was $6.0 million, down 60.0% from the prior year.
• Capital Expenditures improved to $1.0 million in Q1 2026 per RARE's latest filing, from $938000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $95.7 million in Q4 2022 and bottomed at -$42.7 million in Q3 2022.
• Historically, Capital Expenditures has averaged $8.7 million across 5 years, with a median of $2.8 million in 2025.
• Annual changes were most pronounced in 2022 — Capital Expenditures plunged 307.55% — and 2025, when it jumped 830.71%.
• Ultragenyx Pharmaceutical's Capital Expenditures stood at $95.7 million in 2022, then slumped by 134.14% to -$32.7 million in 2023, then surged by 124.99% to $8.2 million in 2024, then tumbled by 88.51% to $938000.0 in 2025, then climbed by 6.61% to $1.0 million in 2026.
• Business Quant data shows RARE's Capital Expenditures at $1.0 million in Q1 2026, $938000.0 in Q4 2025, and $1.3 million in Q3 2025.